Products for Research Use Only
RegisterLogin

Divozilimab

CAT: 0804-HY-P99855-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99855-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20) . Divozilimab can be used for multiple sclerosis research[1].
CAS Number
2254061-60-2
Product Name Alternative
BCD-132
UNSPSC
12352203
Target
CD20
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/divozilimab.html
Purity
99.63
Solubility
10 mM in DMSO
Smiles
[Divozilimab]
Molecular Weight
(145.26 kDa)
References & Citations
[1]O V Boyko, et al. Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132) : pharmacokinetics, pharmacodynamics and safety. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119 (10. Vyp. 2) :87-95.|[2]Boyko AN, et al. Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123 (4) :37-47. Russian.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3

Alternative Products

CatalogName
T77160-01Divozilimab
GTR18338257-01Divozilimab Antibody
A2823-1mg*5Divozilimab (Anti-CD20)
HY257186-01Research Grade Divozilimab
E55B0784Divozilimab (Reference antibody)
591796CD20 (Divozilimab Biosimilar)
048236CD20 (divozilimab) discontinued
F1160-1Anti-CD20 Antibody (Divozilimab)
A138367Divozilimab Biosimilar (Monoclonal, IgG1)
ICH5483-20mgDivozilimab Biosimilar - Research Grade

Popular Products